|
Dr. Kausik Ray on BETonMACE
|
6
|
Resverlogix Corp.
|
Dec 07, 2019 03:08PM
|
|
Drug Discovery Targeting BRD4
|
7
|
Resverlogix Corp.
|
Oct 04, 2017 02:23PM
|
|
Emergent expansion of clinical epigenetics in CVD
|
10
|
Resverlogix Corp.
|
Feb 27, 2021 11:35PM
|
|
Epigenetic Markers of Alzheimers
|
|
Resverlogix Corp.
|
Dec 07, 2019 11:17PM
|
|
Epilepsy? Two links with partial quote from the first
|
2
|
Resverlogix Corp.
|
Aug 22, 2020 06:39AM
|
|
ESC highlights
|
1
|
Resverlogix Corp.
|
Aug 29, 2021 04:56PM
|
|
European Medical Journal - Sorry if posted already, didn't see
|
2
|
Resverlogix Corp.
|
Nov 06, 2015 07:09PM
|
|
Fabrazyme for Fabry
|
|
Resverlogix Corp.
|
Apr 01, 2021 06:17AM
|
|
Fabry competition
|
4
|
Resverlogix Corp.
|
Feb 27, 2021 11:45PM
|
|
Fierce Biotech Article
|
1
|
Zenith Epigenetics
|
Jul 01, 2021 09:35PM
|
|
Finally got around to this. UN-official, of course
|
8
|
Resverlogix Corp.
|
Sep 16, 2015 06:23PM
|
|
Gender differences in responses to BET inhibition
|
|
Resverlogix Corp.
|
Apr 29, 2021 08:32AM
|
|
Gene therapy for Fabry - maybe good news for patients - competition for RVX or complimentary??
|
1
|
Resverlogix Corp.
|
Sep 09, 2020 10:04PM
|
|
Going back to March/April
|
4
|
Resverlogix Corp.
|
Aug 03, 2022 02:08PM
|
|
Good grief- sorry
|
3
|
Resverlogix Corp.
|
Nov 10, 2021 10:51AM
|
|
Here's one while we wait again - inflammation & obesity (huge market)
|
3
|
Resverlogix Corp.
|
Feb 13, 2018 04:53PM
|
|
How common is this infectious pathway, or whatever the correct term is?
|
6
|
Resverlogix Corp.
|
Jan 03, 2021 08:27PM
|
|
Icosapent Ethyl
|
1
|
Resverlogix Corp.
|
Apr 13, 2020 04:42PM
|
|
In Brief Published: 14 May 2021 CARDIOVASCULAR RISK Apabetalone in chronic kidney disease
|
3
|
Resverlogix Corp.
|
May 21, 2021 01:54AM
|
|
Interesting article on UK study - re: COVID
|
|
Resverlogix Corp.
|
Jul 27, 2020 08:18PM
|
